EndoPredict® is a multi-gene test for breast cancer patients.
Using a specially developed procedure, EndoPredict provides physicians with information to devise personalized treatment plans for their breast cancer patients. The EndoPredict test kit format is an ideal platform for use by clinical pathologists, who desire to conduct testing within their own laboratories. The method is based on analysis of tumour genes in combination with the classical prognostic factors of nodal status and tumour size.In contrast to older multi-gene tests, EndoPredict detects the likelihood of late metastases (i.e., metastasis formation after more than five years) and can thus guide treatment decisions for chemotherapy as well as extended anti-hormonal therapy. Accordingly, therapy decisions backed by EndoPredict confer a high level of diagnostic confidence. EndoPredict was shown to accurately predict cancer-specific disease progression and metastasis in multiple clinical outcome studies with more than 3,000 patients.